£8 million funding for new start-up TopiVert

12-Dec-2011 - United Kingdom

Imperial Innovations Group plc  and SV Life Sciences have committed to invest £8 million in a new start-up company TopiVert, which will focus on developing topical medicines for inflammatory diseases of the eye and gut.

TopiVert has licensed NSKI (narrow spectrum kinase inhibitor) related intellectual property from RespiVert Ltd., a former Imperial Innovations portfolio company acquired by Janssen Biotech, Inc. (formerly known as Centocor Ortho Biotech Inc.) in 2010, for TopiVert’s exclusive use in discovering and developing NSKIs for inflammatory diseases of the eye and gut. Both participants in this funding round were also investors in RespiVert.

TopiVert will enter into an exclusive drug discovery collaboration with RespiVert aimed at identifying new NSKIs.  TopiVert will receive exclusive rights to select and develop resulting NSKIs for the treatment of inflammatory diseases of the eye and gut, such as uveitis and inflammatory bowel disease, while RespiVert will receive exclusive rights to select and develop resulting NSKIs for the treatment of other indications, such as inflammatory diseases of the lungs. 

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance